试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
编号:NCT01101906登记状态:提前终止企业 / 申办者:Astellas Pharma Inc
药物 / 成分:OSI-906、Placebo
登记的停止原因(原文):Company decided not to pursue the development of this drug in this patient population at this time
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
编号:NCT01982071登记状态:提前终止企业 / 申办者:Astellas Pharma China, Inc.
药物 / 成分:Micafungin
登记的停止原因(原文):Due to administrative reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
编号:NCT02317783登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:[18F]Flutemetamol、[18F]fluoro-2-deoxy-D-glucose (FDG)、Functional Magnetic Resonance Imaging (fMRI)
登记的停止原因(原文):Enrollment challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
编号:NCT02500927登记状态:提前终止企业 / 申办者:Astellas Pharma Inc
药物 / 成分:ASP8273 Capsules、ASP8273 Capsules A
登记的停止原因(原文):Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
编号:NCT02646774登记状态:提前终止企业 / 申办者:Astellas Pharma China, Inc.
药物 / 成分:Micafungin
登记的停止原因(原文):Due to administrative reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
编号:NCT03082300登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:naquotinib
登记的停止原因(原文):Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
编号:NCT03486197登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Laboratory Biomarker Analysis、Pembrolizumab、Radiation Therapy
登记的停止原因(原文):Closed per SRC Low Accrual Policy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
编号:NCT04170023登记状态:提前终止企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:ALXN2050
登记的停止原因(原文):Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
ESKETamine for FIBromyalgia Treatment
编号:NCT04436250登记状态:提前终止企业 / 申办者:Grand Hôpital de Charleroi
药物 / 成分:Active comparator、S-Ketamine Low dose、S-Ketamine High dose
登记的停止原因(原文):Lack of recruitment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults
编号:NCT05167526登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:ASP8731、ASP8731 Matching Placebo
登记的停止原因(原文):The study was terminated due to protocol defined stopping criteria being met.
查看官方原始记录 ↗